Anand Shah, M.D. is a nationally recognized physician leader and health policy expert who most recently served as the Deputy Commissioner for Medical and Scientific Affairs at the U.S. Food and Drug Administration (FDA). Dr. Shah’s efforts have focused on bringing new technologies to market, redesigning health care delivery and economic incentives, and expanding competition and consumer choice. At FDA, Dr. Shah led consensus policy development for fit-for-purpose programs including pandemic recovery and preparedness, Advanced Manufacturing, the Coronavirus Treatment Acceleration Program, COVID-19 vaccine development, digital health, consumer protection, and decentralized clinical trials. He developed a science and technology incubator designed to harness real-world evidence and artificial intelligence to improve health outcomes. Dr. Shah represented FDA with top-level policy makers of the White House and Cabinet, Governors, and local governments. He regularly briefed bipartisan bicameral Congressional leadership on the formulation of public health policies and programs.
He previously served in two senior leadership roles at the Centers for Medicare & Medicaid Services (CMS). As Senior Medical Advisor, he was the primary counselor for agency-wide policy related to medical and scientific innovation. Dr. Shah established consensus on several critical policy initiatives including aligning payment and prevention to increase Medicare beneficiaries’ access to novel antimicrobials, expanding patients’ access to cell and gene therapies, and streamlining Medicare access to breakthrough technologies. As the Chief Medical Officer of the Center for Medicare & Medicaid Innovation (CMMI), Dr. Shah led the clinical design of novel value-based payment and service delivery models including those for advanced primary care, specialty care, and prescription drugs.
Dr. Shah specializes in the early detection, surveillance, and treatment of prostate cancer. He developed and led a survivorship clinic for the care of patients on cancer clinical trials at the National Institutes of Health. He has served as an Adjunct Senior Fellow at the Leonard Davis Institute of Health Economics at the University of Pennsylvania. Dr. Shah completed a health economics fellowship at the University of Pennsylvania where he developed and applied significant expertise with economic, financial, and valuation modeling of emerging therapeutics. Dr. Shah was on Duke University faculty where he led the Center for Excellence in Surgical Outcomes as its Associate Director. He has received research funding from government and philanthropic sources. His scientific track record includes publications in the New England Journal of Medicine, JAMA, Health Affairs, Cancer, and Nature Reviews Drug Discovery.
Dr. Shah was chief resident during his radiation oncology residency at Columbia University. He concurrently earned his M.D. from the University of Pennsylvania and an M.P.H. in health care management and policy from the Harvard School of Public Health. Dr. Shah graduated with honors from Duke University with a degree in economics. He also served as a Canada-U.S. Fulbright Scholar.
Aanand Shah, MD